Global Blood Therapeutics, Inc. to Post FY2018 Earnings of ($3.30) Per Share, SunTrust Banks Forecasts (GBT)
Global Blood Therapeutics, Inc. (NASDAQ:GBT) – Equities research analysts at SunTrust Banks raised their FY2018 earnings per share (EPS) estimates for Global Blood Therapeutics in a research note issued to investors on Monday. SunTrust Banks analyst Y. Suneja now expects that the company will post earnings of ($3.30) per share for the year, up from their previous forecast of ($4.10). SunTrust Banks currently has a “Buy” rating and a $67.00 price target on the stock. SunTrust Banks also issued estimates for Global Blood Therapeutics’ FY2019 earnings at ($3.45) EPS, FY2020 earnings at ($3.55) EPS and FY2021 earnings at ($4.40) EPS.
Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same period in the previous year, the firm earned ($0.58) EPS.
Global Blood Therapeutics (GBT) traded up $3.55 during mid-day trading on Wednesday, hitting $43.85. 1,371,600 shares of the company were exchanged, compared to its average volume of 988,892. Global Blood Therapeutics has a 1-year low of $13.35 and a 1-year high of $44.30.
In other news, Director Charles J. Homcy sold 70,000 shares of the company’s stock in a transaction dated Friday, October 27th. The stock was sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now directly owns 83,328 shares of the company’s stock, valued at approximately $2,830,652.16. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jung Choi sold 3,000 shares of the company’s stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $32.65, for a total value of $97,950.00. Following the completion of the sale, the insider now directly owns 138,455 shares of the company’s stock, valued at $4,520,555.75. The disclosure for this sale can be found here. Insiders have sold a total of 88,500 shares of company stock valued at $3,003,350 over the last three months. Company insiders own 5.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA boosted its position in Global Blood Therapeutics by 694.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock worth $124,000 after acquiring an additional 3,975 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Global Blood Therapeutics by 10.1% during the first quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock valued at $178,000 after buying an additional 440 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Global Blood Therapeutics during the third quarter valued at approximately $200,000. Trexquant Investment LP purchased a new position in Global Blood Therapeutics in the third quarter worth $202,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Global Blood Therapeutics in the third quarter worth $205,000. 90.48% of the stock is owned by institutional investors and hedge funds.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.